116 related articles for article (PubMed ID: 9129992)
1. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha.
Shannon EJ; Sandoval F; Krahenbuhl JL
Immunopharmacology; 1997 Apr; 36(1):9-15. PubMed ID: 9129992
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide.
Shannon E; Noveck R; Sandoval F; Kamath B
Immunopharmacol Immunotoxicol; 2008; 30(3):447-57. PubMed ID: 18668392
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood.
Shannon E; Aseffa A; Pankey G; Sandoval F; Lutz B
Immunopharmacology; 2000 Feb; 46(2):175-9. PubMed ID: 10647875
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells.
Shannon EJ; Sandoval F
Immunopharmacol Immunotoxicol; 1996 Feb; 18(1):59-72. PubMed ID: 8683039
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory assays to study structure-activity relationships of thalidomide.
Shannon EJ; Morales MJ; Sandoval F
Immunopharmacology; 1997 Jan; 35(3):203-12. PubMed ID: 9043933
[TBL] [Abstract][Full Text] [Related]
6. Effect of thalidomide on the expression of TNF-alpha m-RNA and synthesis of TNF-alpha in cells from leprosy patients with reversal reaction.
Tadesse A; Abebe M; Bizuneh E; Mulugeta W; Aseffa A; Shannon EJ
Immunopharmacol Immunotoxicol; 2006; 28(3):431-41. PubMed ID: 16997792
[TBL] [Abstract][Full Text] [Related]
7. Novel thalidomide analogues from diamines inhibit pro-inflammatory cytokine production and CD80 expression while enhancing IL-10.
Mazzoccoli L; Cadoso SH; Amarante GW; de Souza MV; Domingues R; Machado MA; de Almeida MV; Teixeira HC
Biomed Pharmacother; 2012 Jul; 66(5):323-9. PubMed ID: 22770990
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia.
Shannon E; Noveck R; Sandoval F; Kamath B; Kearney M
Transl Res; 2007 Nov; 150(5):275-80. PubMed ID: 17964516
[TBL] [Abstract][Full Text] [Related]
9. Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone.
Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I
Immunol Lett; 1999 Jun; 68(2-3):325-32. PubMed ID: 10424439
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide does not modify the ability of cells in leprosy patients to incorporate [3H]-thymidine when incubated with M. leprae antigens.
Tadesse A; Taye E; Sandoval F; Shannon EJ
Lepr Rev; 2003 Sep; 74(3):206-14. PubMed ID: 14577465
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors.
Chaulet C; Croix C; Alagille D; Normand S; Delwail A; Favot L; Lecron JC; Viaud-Massuard MC
Bioorg Med Chem Lett; 2011 Feb; 21(3):1019-22. PubMed ID: 21215621
[TBL] [Abstract][Full Text] [Related]
12. Trans-10, cis-12-conjugated linoleic acid attenuates tumor necrosis factor-α production by lipopolysaccharide-stimulated porcine peripheral blood mononuclear cells through induction of interleukin-10.
Kim KH; Kim DI; Kim SH; Jung EM; Kang JH; Jeung EB; Yang MP
Cytokine; 2011 Nov; 56(2):224-30. PubMed ID: 21795062
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.
Bauditz J; Wedel S; Lochs H
Gut; 2002 Feb; 50(2):196-200. PubMed ID: 11788559
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis.
Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G
Clin Exp Immunol; 1999 Nov; 118(2):315-21. PubMed ID: 10540197
[TBL] [Abstract][Full Text] [Related]
15. [Effect of gamma-plant preparation on production of TNF-alpha, IL-1 beta, and IL-6 in human peripheral blood mononuclear cells in vitro].
Chekanovskaia LA; Generalov AV
Vopr Med Khim; 2001; 47(2):263-73. PubMed ID: 11450448
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.
Eigler A; Siegmund B; Emmerich U; Baumann KH; Hartmann G; Endres S
J Leukoc Biol; 1998 Jan; 63(1):101-7. PubMed ID: 9469479
[TBL] [Abstract][Full Text] [Related]
17. A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis.
Takabayashi T; Vannier E; Clark BD; Margolis NH; Dinarello CA; Burke JF; Gelfand JA
J Immunol; 1996 May; 156(9):3455-60. PubMed ID: 8617973
[TBL] [Abstract][Full Text] [Related]
18. Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs.
Goosen C; Laing TJ; du Plessis J; Goosen TC; Rao TB; Flynn GL
Pharm Res; 2002 Aug; 19(8):1232-5. PubMed ID: 12240951
[TBL] [Abstract][Full Text] [Related]
19. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.
Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG
J Immunol; 1998 Oct; 161(8):4236-43. PubMed ID: 9780198
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide can costimulate or suppress CD4+ cells' ability to incorporate [H3]-thymidine--dependence on the primary stimulant.
Shannon EJ; Sandoval FG
Int Immunopharmacol; 2002 Jul; 2(8):1143-53. PubMed ID: 12349951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
